The FDA has responded to the increasing use of artificial intelligence (AI) in the discovery and development of drugs and ...

The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...

Where early enthusiasm around IDMP programmes had waned in response to slow progress from EMA in Europe towards clarifying ...

Now, in 2025, we expect the life sciences industry will scale its use of GenAI with greater purpose. As these applications ...

Chief executive David Zaccardelli said Ohtuvayre was off to an "exceptionally strong start," with more than 3,500 healthcare ...

1. Proactively identify barriers to medication adherence, including identifying and targeting patients who may be ...

The unidentified man is one of 66 confirmed human cases of H5N1 bird flu in the US since 2024, when the current outbreak took ...

Fortunately, my home isn't too far from Stamford Bridge stadium, making it easy to catch the action live! Connect with Peter ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will ...